Original Article
Study on CYP2C19 gene polymorphism in patients with coronary heart disease and cerebrovascular disease in Weihai area
Xiangying Ma, Conghui Tan, Sen Liu, Qi Gong, Yifan Guo, Jinhuan Wang, Daoqiang Zhang
Published 2019-10-15
Cite as Int J Genet, 2019, 42(5): 327-331. DOI: 10.3760/cma.j.issn.1673-4386.2019.05.002
Abstract
ObjectiveTo investigate the distribution characteristics of CYP2C19 gene polymorphism in patients with cardiovascular and cerebrovascular diseases in this area, and to explain the importance of drug gene detection to guide the clinical use of clopidogrel.
MethodsA total of 964 patients with cardiovascular and cerebrovascular diseases were selected from the CYP2C19 gene polymorphism in our hospital from 2016 to 2018. The CYP2C19*2, *3 and *17 alleles were detected by real-time fluorescence quantitative PCR. The metabolic phenotype was judged according to the genotype, and the correlation between gender and clinical classification of diseases and CYP2C19 gene polymorphism was analyzed.
ResultsA total of 8 genotypes were detected in this study: CYP2C19*1*17, *1*1, *1*2, *1*3, *2*17, *2*2, *2*3, *3 *3, of which *1/*1 has the highest incidence rate, the frequency is 39.2%; and the metabolic phenotypes: UM(1.5%), EM(39.2%), IM(46.3%)and PM(13%), the proportion of IM was the most abundant. There was no significant difference in CYP2C19 genotype and metabolic phenotype between clinical isolates of different genders and diseases(P>0.05).
ConclusionThe CYP2C19 gene is polymorphic in patients with cardiovascular and cerebrovascular diseases in this region. The CYP2C19 genotype is mainly CYP2C19*1/*1, and the metabolic phenotype is mainly intermediate metabolites. The distribution of allele frequency and metabolic phenotype of the CYP2C19 gene is similar to that in Asians. According to the genotype, clopidogrel antiplatelet therapy is of great significance for clinical individualized medication.
Key words:
Coronary heart disease; Cerebrovascular disease; CYP2C19 gene; Clopidogrel; Individualized medication
Contributor Information
Xiangying Ma
Department of Medical Laboratory Science, Weifang Medical University, Weifang 261053, China
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Conghui Tan
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Weihai Central Hospital Central Laboratory, Weihai 264400, China
Sen Liu
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Department of Cardiology, Weihai Central Hospital, Weihai 264400, China
Qi Gong
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Weihai Central Hospital Central Laboratory, Weihai 264400, China
Yifan Guo
Department of Medical Laboratory Science, Weifang Medical University, Weifang 261053, China
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Jinhuan Wang
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Weihai Central Hospital Central Laboratory, Weihai 264400, China
Daoqiang Zhang
Weihai Key Laboratory of Autoimmune Immunology, Weihai 264400, China
Weihai Central Hospital Central Laboratory, Weihai 264400, China
